Remicade Binding Assays

BioOutsource has extensive experience in the development, optimisation and validation of a wide range of different types of binding assays and immunoassays for Remicade and offers GCP, GLP and cGMP testing services in compliance with EMA and FDA guidelines to support the biopharmaceutical industry.
Using this experience, we have created a range of off-the-shelf binding assays, including Remicade TNF-Alpha binding assay, Remicade C1q binding assay, Remicade FcRn binding assay and Remicade Fc-Gamma Receptor binding assays to support characterization and similarity studies.

Binding assays are employed to study a number of different features of Remicade (infliximab) and play a vital role in the development process and in characterization and similarity studies, to measure the binding of Remicade to TNF-Alpha as well as C1q, the Fc Gamma Receptors (FcR) and the neonatal Fc Receptor (FcRn). BioOutsource offers a comprehensive range of off-the-shelf generic binding methods to support the characterization of Remicade (infliximab) and performance of extensive biosimilarity studies:

These methods have been developed using different platforms including ELISA, Electrochemiluminescence (MSD) or Surface Plasmon Resonance and can be performed with a variety of different reporting mechanisms including affinity, on and off rates as well as relative binding using a totality of data evaluation approach to provide you with comprehensive, industry-leading comparability reports to understand all aspects of the performance of your Remicade molecule.

BioOutsource offers cost-effective solutions to develop custom methods that are not currently in our portfolio please contact us to find out more.